https://www.targetedonc.com/view/promising-imaging-results-seen-with-64cu-sar-bombesin-in-prostate-cancer
0
0
9/14/23 at 7:11pm
Organization
Targetedonc.com
Author
Jordyn Sava
37 words
0
Comments
No adverse events were associated with 64Cu-SAR-Bombesin treatment in patients with prostate cancer, according to findings from the phase 2 BOP trial.
You are the first to view
Create an account
or login to join the discussion